1
|
He S, Guan Y, Wu Y, Zhu L, Yan B, Honda H, Yang J, Liu W. DEC1 deficiency results in accelerated osteopenia through enhanced DKK1 activity and attenuated PI3KCA/Akt/GSK3β signaling. Metabolism 2021; 118:154730. [PMID: 33607194 PMCID: PMC8311383 DOI: 10.1016/j.metabol.2021.154730] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/24/2020] [Revised: 02/02/2021] [Accepted: 02/09/2021] [Indexed: 12/22/2022]
Abstract
BACKGROUND Human differentiated embryonic chondrocyte expressed gene 1 (DEC1) has been implicated in enhancing osteogenesis, a desirable outcome to counteract against deregulated bone formation such as retarded bone development, osteopenia and osteoporosis. METHODS AND RESULTS DEC1 knockout (KO) and the age-matched wild-type (WT) mice were tested for the impact of DEC1 deficiency on bone development and osteopenia as a function of age. DEC1 deficiency exhibited retarded bone development at the age of 4 weeks and osteopenic phenotype in both 4- and 24-week old mice. However, the osteopenia was more severe in the 24-week age groups. Mechanistically, DEC1 deficiency downregulated the expression of bone-enhancing genes such as Runx2 and β-catenin accompanied by upregulating DKK1, an inhibitor of the Wnt/β-catenin signaling pathway. Consistently, DEC1 deficiency favored the attenuation of the integrated PI3KCA/Akt/GSK3β signaling, a pathway targeting β-catenin for degradation. Likewise, the attenuation was greater in the 24-week age group. These changes, however, were reversed by in vivo treatment with lithium chloride, a stabilizer of β-catenin, and confirmed by gain-of-function study with DEC1 transfection into DEC1 KO bone marrow mesenchymal stem cells and loss-of-function study with siDEC1 lentiviral infection into the corresponding WT cells. CONCLUSION DEC1 is a positive regulator with a broad activity spectrum in both bone development and maintenance, and the osteopenic phenotype accelerated by DEC1 deficiency is achieved by enhanced DKK1 activity and attenuated PI3KCA/Akt/GSK3β signaling.
Collapse
Affiliation(s)
- Shuangcheng He
- Department of Pharmacology, Nanjing Medical University, China
| | - Yu Guan
- Department of Pharmacology, Nanjing Medical University, China
| | - Yichen Wu
- Department of Pharmacology, Nanjing Medical University, China
| | - Ling Zhu
- Department of Pharmacology, Nanjing Medical University, China
| | - Bingfang Yan
- James L. Winkle College of Pharmacy University of Cincinnati, Cincinnati, OH 45229, USA
| | - Hiroaki Honda
- Research Institute for Radiation Biology and Medicine, Hiroshima University, Japan
| | - Jian Yang
- Department of Pharmacology, Nanjing Medical University, China
| | - Wei Liu
- Department of Pharmacology, Nanjing Medical University, China
| |
Collapse
|
2
|
Deniz AAH, Abdik EA, Abdik H, Aydın S, Şahin F, Taşlı PN. Zooming in across the Skin: A Macro-to-Molecular Panorama. ADVANCES IN EXPERIMENTAL MEDICINE AND BIOLOGY 2020; 1247:157-200. [DOI: 10.1007/5584_2019_442] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
|
3
|
Luo W, Xu C, Ayello J, Dela Cruz F, Rosenblum JM, Lessnick SL, Cairo MS. Protein phosphatase 1 regulatory subunit 1A in ewing sarcoma tumorigenesis and metastasis. Oncogene 2017; 37:798-809. [PMID: 29059150 DOI: 10.1038/onc.2017.378] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/25/2017] [Revised: 09/05/2017] [Accepted: 09/07/2017] [Indexed: 02/06/2023]
Abstract
Protein phosphatase inhibitors are often considered as tumor promoters. Protein phosphatase 1 regulatory subunit 1A (PPP1R1A) is a potent protein phosphatase 1 (PP1) inhibitor; however, its role in tumor development is largely undefined. Here we characterize, for the first time, the functions of PPP1R1A in Ewing sarcoma (ES) pathogenesis. We found that PPP1R1A is one of the top ranked target genes of EWS/FLI, the master regulator of ES, and is upregulated by EWS/FLI via a GGAA microsatellite enhancer element. Depletion of PPP1R1A resulted in a significant decrease in oncogenic transformation and cell migration in vitro as well as xenograft tumor growth and metastasis in an orthotopic mouse model. RNA-sequencing and functional annotation analyses revealed that PPP1R1A regulates genes associated with various cellular functions including cell junction, adhesion and neurogenesis. Interestingly, we found a significant overlap of PPP1R1A-regulated gene set with that of ZEB2 and EWS, which regulates metastasis and neuronal differentiation in ES, respectively. Further studies for characterization of the molecular mechanisms revealed that activation of PPP1R1A by PKA phosphorylation at Thr35, and subsequent PP1 binding and inhibition, was required for PPP1R1A-mediated tumorigenesis and metastasis, likely by increasing the phosphorylation levels of various PP1 substrates. Furthermore, we found that a PKA inhibitor impaired ES cell proliferation, tumor growth and metastasis, which was rescued by the constitutively active PPP1R1A. Together, these results offered new insights into the role and mechanism of PPP1R1A in tumor development and identified an important kinase and phosphatase pathway, PKA/PPP1R1A/PP1, in ES pathogenesis. Our findings strongly suggest a potential therapeutic value of inhibition of the PKA/PPP1R1A/PP1 pathway in the treatment of primary and metastatic ES.
Collapse
Affiliation(s)
- W Luo
- Departments of Pediatrics, New York Medical College, Valhalla, NY, USA.,Departments of Pathology, New York Medical College, Valhalla, NY, USA
| | - C Xu
- James J. Peters Veterans Affairs Medical Center, Bronx, NY, USA
| | - J Ayello
- Departments of Pediatrics, New York Medical College, Valhalla, NY, USA
| | - F Dela Cruz
- Memorial Sloan Kettering Cancer Center, New York, NY, USA
| | - J M Rosenblum
- Departments of Pediatrics, New York Medical College, Valhalla, NY, USA
| | - S L Lessnick
- Nationwide Children's Hospital, Columbus, OH, USA
| | - M S Cairo
- Departments of Pediatrics, New York Medical College, Valhalla, NY, USA.,Departments of Pathology, New York Medical College, Valhalla, NY, USA.,Departments of Medicine, New York Medical College, Valhalla, NY, USA.,Departments of Immunology and Microbiology, New York Medical College, Valhalla, NY, USA.,Departments of Cell Biology and Anatomy, New York Medical College, Valhalla, NY, USA
| |
Collapse
|
4
|
Tannenbaum-Dvir S, Glade Bender JL, Church AJ, Janeway KA, Harris MH, Mansukhani MM, Nagy PL, Andrews SJ, Murty VV, Kadenhe-Chiweshe A, Connolly EP, Kung AL, Dela Cruz FS. Characterization of a novel fusion gene EML4-NTRK3 in a case of recurrent congenital fibrosarcoma. Cold Spring Harb Mol Case Stud 2016; 1:a000471. [PMID: 27148571 PMCID: PMC4850889 DOI: 10.1101/mcs.a000471] [Citation(s) in RCA: 33] [Impact Index Per Article: 4.1] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022] Open
Abstract
We describe the clinical course of a recurrent case of congenital fibrosarcoma diagnosed in a 9-mo-old boy with a history of hemimelia. Following complete surgical resection of the primary tumor, the patient subsequently presented with bulky bilateral pulmonary metastases 6 mo following surgery. Molecular characterization of the tumor revealed the absence of the prototypical ETV6-NTRK3 translocation. However, tumor characterization incorporating cytogenetic, array comparative genomic hybridization, and RNA sequencing analyses, revealed a somatic t(2;15)(2p21;15q25) translocation resulting in the novel fusion of EML4 with NTRK3. Cloning and expression of EML4-NTRK3 in murine fibroblast NIH 3T3 cells revealed a potent tumorigenic phenotype as assessed in vitro and in vivo. These results demonstrate that multiple fusion partners targeting NTRK3 can contribute to the development of congenital fibrosarcoma.
Collapse
Affiliation(s)
- Sarah Tannenbaum-Dvir
- Columbia University Medical Center, Department of Pediatric Oncology/Hematology/Stem Cell Transplantation, Department of Pediatrics, New York, New York 10032, USA
| | - Julia L Glade Bender
- Columbia University Medical Center, Department of Pediatric Oncology/Hematology/Stem Cell Transplantation, Department of Pediatrics, New York, New York 10032, USA
| | - Alanna J Church
- Harvard Medical School, Department of Pathology, Boston, Massachusetts 02115, USA
| | - Katherine A Janeway
- Harvard Medical School, Department of Pediatric Oncology/Hematology, Boston, Massachusetts 02115, USA
| | - Marian H Harris
- Harvard Medical School, Department of Pathology, Boston, Massachusetts 02115, USA
| | - Mahesh M Mansukhani
- Columbia University Medical Center, Department of Pathology and Cell Biology, New York, New York 10032, USA
| | - Peter L Nagy
- Columbia University Medical Center, Department of Pathology and Cell Biology, New York, New York 10032, USA
| | - Stuart J Andrews
- Columbia University Medical Center, Department of Pathology and Cell Biology, New York, New York 10032, USA
| | - Vundavalli V Murty
- Columbia University Medical Center, Department of Pathology and Cell Biology, New York, New York 10032, USA
| | | | - Eileen P Connolly
- Columbia University Medical Center, Department of Radiation Oncology, New York, New York 10032, USA
| | - Andrew L Kung
- Columbia University Medical Center, Department of Pediatric Oncology/Hematology/Stem Cell Transplantation, Department of Pediatrics, New York, New York 10032, USA
| | - Filemon S Dela Cruz
- Columbia University Medical Center, Department of Pediatric Oncology/Hematology/Stem Cell Transplantation, Department of Pediatrics, New York, New York 10032, USA
| |
Collapse
|
5
|
Effects of constitutive β-catenin activation on vertebral bone growth and remodeling at different postnatal stages in mice. PLoS One 2013; 8:e74093. [PMID: 24066100 PMCID: PMC3774640 DOI: 10.1371/journal.pone.0074093] [Citation(s) in RCA: 15] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/07/2013] [Accepted: 07/26/2013] [Indexed: 11/19/2022] Open
Abstract
Background and Objective The Wnt/β-catenin signaling pathway is essential for controlling bone mass; however, little is known about the variable effects of the constitutive activation of β-catenin (CA-β-catenin) on bone growth and remodeling at different postnatal stages. The goal of the present study was to observe the effects of CA-β-catenin on vertebral bone growth and remodeling in mice at different postnatal stages. In particular, special attention was paid to whether CA-β-catenin has detrimental effects on these processes. Methods Catnblox(ex 3) mice were crossed with mice expressing the TM-inducible Cre fusion protein, which could be activated at designated time points via injection of tamoxifen. β-catenin was stabilized by tamoxifen injection 3 days, and 2, 4, 5, and 7 months after birth, and the effects lasted for one month. Radiographic imaging, micro-computed tomography, immunohistochemistry, and safranin O and tartrate-resistant acid phosphatase staining were employed to observe the effects of CA-β-catenin on vertebral bone growth and remodeling. Results CA-β-catenin in both early (3 days after birth) and late stages (2, 4, 5, and 7 months after birth) increased bone formation and decreased bone resorption, which together increased vertebral bone volume. However, when β-catenin was stabilized in the early stage, vertebral linear growth was retarded, and the mice demonstrated shorter statures. In addition, the newly formed bone was mainly immature and located close to the growth plate. In contrast, when β-catenin was stabilized in the late stage, vertebral linear growth was unaffected, and the newly formed bone was mainly mature and evenly distributed throughout the vertebral body. Conclusions CA-β-catenin in both early and late stages of growth can increase vertebral bone volume, but β-catenin has differential effects on vertebral growth and remodeling when activated at different postnatal stages.
Collapse
|